Questions with no answer at all. Not questions with no accepted answer — those are elsewhere.
The specifics, since they change the answer: tirzepatide · Shanghai. I am at the decision point and I would rather think it through than improvise. I would rather…
For reference: ATTAIN-1 · ecnoglutide. I would like to know whether this claim survives contact with evidence. If the answer is "nobody has tested that", I would like…
This is the third vial from the same lot, so I can compare against two known-good ones. I would like to know whether this claim survives contact with evidence. If the…
Conditions: an escrowed payment · Australia. The failure mode I am trying to avoid is making this decision emotionally. I have twelve months in view and I would like…
The case in front of me: PIONEER-1 · tirzepatide. The claim is plausible, which is exactly why I want to check it. I am able to read a paper if someone points me at…
I have three DEXA scans on the same scanner at twelve-week intervals, fasted, same time of day. The comparison I want does not seem to exist anywhere in a form I can…
I have been on a stable schedule for eleven weeks, so this is not a first-week question. This is presented as though it settles something, and I am not convinced it…
The case in front of me: HJ · Tianjin · the United Kingdom. I want to decide this in advance so that I am not deciding it under pressure later. Assume I will follow…
I have the plan documents and the written criteria, which took two calls to obtain. I have read the obvious sources and they disagree with each other, so I would…
Stated plainly: dimerisation · a GLP-1 receptor agonist · 25 °C. The empirical answer seems settled. The explanation does not. If the honest answer is that nobody…
Details up front: fatigue · seven · oral semaglutide. I can find plenty of assertions about this and almost no reasoning, which is usually a sign that nobody has…
Numbers first: 3.33 mg/mL · orforglipron. I want to know what the trade-off actually is rather than which option is fashionable. I would rather have a defensible…
The particulars: 50 mg · 1 mg/mL. I would rather understand the derivation than memorise the outcome. Two people I asked gave two answers that differ by a factor of…
What I am working with: 20 mg · a GLP-1 receptor agonist. I keep seeing this stated as a fact with no explanation attached, and unexplained facts make me suspicious.…
Conditions: 2.5 mg · 1 mL · 0.9% sodium chloride. Please show the division. I want to check my own against yours. I would like the general form as well as the…
Stated plainly: ERP · GL Biochem (Shanghai). Both of these get recommended confidently by different people, which suggests neither is obviously right. My constraints…
Numbers first: a GLP-1 receptor agonist · PIONEER-1. I suspect the usual explanation for this is wrong, or at least incomplete. I am aware this may have a boring…
What I have: SURMOUNT-1 · nausea. This is presented as though it settles something, and I am not convinced it does. I have two documents that appear to disagree,…
The clinician who ordered the panel was not concerned; I would still like to understand it. This is one of those things that everyone repeats and nobody derives. This…
What I am working with: retatrutide · 8 mg/mL. I am trying to build something sustainable rather than something thorough that I will abandon. I have already decided…
What I have: a GLP-1 receptor agonist · 4 mg/mL. This is a planning question. I know what my options are; I do not know how to weigh them. What I want is the minimum…
The case in front of me: Homopeptide · Wuhan Wansheng Biotechnology. I would like the axes of comparison first and the recommendation second. I have tried the first…
Stated plainly: retatrutide · 30 °C. This is a procedural question rather than a theoretical one, and I would like the procedure rather than the theory. What I have…
It has now persisted for three weeks, which is what moved this from tolerable to worth asking about. This is presented as though it settles something, and I am not…